Phase I study of perillyl alcohol in patients with refractory malignancies

Cancer Biology and Therapy

Volumn 1, Issue 2, 2002, Pages 130-135

  Murren, John R ^a   Pizzorno, Giuseppe ^a   DiStasio, Susan A ^a   McKeon, Anne ^a   Peccerillo, Kathleen ^a   Gollerkari, Ashwin ^a   McMurray, Walter ^a   Burtness, Barbara A ^a   Rutherford, Thomas ^a   Li, Xin ^a   Ho, Peter T C ^a   Sartorelli, Alan ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Dose finding study; Limonene; Monoterpenes; Perillyl alcohol

Indexed keywords

ANTINEOPLASTIC AGENT; PERILLYL ALCOHOL; TERPENE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOTERPENES; NEOPLASMS; TERPENES;

EID: 0036491156     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.57     Document Type: Article

References (41)

1. Chayet L, Rojas C, Cardemil E, Jabalquinto AM, Vicuna R, Cori O. Biosynthesis of monoterpene hydrocarbons from [1-3H]neryl pyrophosphate and [1-3H]geranyl pyrophosphate by soluble enzymes from Citrus limonum. Arch Biochem Biophys 1977; 180(2):318-27. (Pubitemid 8115499)
2. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN. Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 1988; 9(2):331-2. (Pubitemid 18038001)
3. Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN. The prevention of nitrosomethylurea-induced mammary tumors by d- limonene and orange oil. Carcinogenesis 1989; 10(4):781-3. (Pubitemid 19101303)
4. Elegbede JA, Maltzman TH, Verma AK, Tanner MA, Elson CE, Gould MN. Mouse skin tumor promoting activity of orange peel oil and d-limonene: a re-evaluation. Carcinogenesis 1986; 7(12):2047-9.
5. Wattenberg LW, Sparnins VL, Barany G. Inhibition of N-nitrosodiethylamine carcinogenesis in mice by naturally occurring organosulfur compounds and monoterpenes. Cancer Res 1989; 49(10):2689-92. (Pubitemid 19143400)
6. Elegbede JA, Elson CE, Tanner MA, Qureshi A, Gould MN. Regression of rat primary mammary tumors following dietary d-limonene. JNCI 1986; 76:323-5. (Pubitemid 16130014)
7. Haag JD, Lindstrom MJ, Gould MN. Limonene-induced regression of mammary carcinomas. Cancer Res 1992; 52:4021-6.
8. Elegbede JA, Elson CE, Qureshi A, Tanner MA, Gould MN. Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. Carcinogenesis 1984; 5(5):661-4. (Pubitemid 14108578)
9. Haag JD, Gould MN. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 1994; 34:477-83. (Pubitemid 24306046)
10. Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett 1995; 96:15-21.
11. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 1997; 127(5):668-74. (Pubitemid 27200738)
12. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 1995; 55:979-83.
13. Shi W, Gould MN. Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol. Cancer Lett 1995; 95:1-6.
14. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 1994; 47:1405-15. (Pubitemid 24130935)
15. Maltzman TH, Christou M, Gould MN, Jefcoate CR. Effects of monoterpenoids on in vivo DMBA-DNA adduct formation and on phase I hepatic metabolizing enzymes. Carcinogenesis 1991; 12(11):2081-7.
16. Austin CA, Shephard EA, Pike SF, Rabin BR, Phillips IR. The effect of terpenoid compounds on cytochrome P-450 levels in rat liver. Biochem Pharmacol 1988; 37(11):2223-9.
17. Boon PJ, van der Boon D, Mulder GJ. Cytotoxicity and biotransformation of the anticancer drug perillyl alcohol in PC12 cells and in the rat. Toxicol Appl Pharmacol 2000; 167(1):55-62. (Pubitemid 30663088)
18. Ren AR, Gould MN. Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol. Cancer Lett 1994; 76:185-90. (Pubitemid 24068295)
19. Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 1995; 270:17508-12.
20. Ariazi EA, Satomi Y, Ellis MJ Haag JD, Shi W, Sattler CA, et al. Activation of tranforming growth factor b signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 1999; 59:1917-28. (Pubitemid 29186166)
21. Bardon S, Picard K, Martel P. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. Nutrition and Cancer 1998; 32:1-7. (Pubitemid 28519235)
22. Elson CE. Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease. J Nutr 1995; 125(6 Suppl):1666S-72S.
23. Montoya RG, Velasco MA, Price RE, L AJ, Wargovich MJ. Pilot study on the chemoprevention of N-Nitrosobis(2-oxopropyl)amine-induced cancers of the pancreas in Syrian golden hamsters by the monoterpene perillyl alcohol. Proc Amer Assoc Cancer Res 1996; 7:274 (abstr 1872).
24. Phillips LR, Malspeis L, Supko JG. Pharmacokinetics of active drug metabolites after the oral administration of perillyl alcohol, an investigational antineoplastic agent, to the dog. Drug Metab Dispos 1995; 23:676-80.
25. Crowell PL, Lin S, Vedejs E, Gould MN. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth. Cancer Chemother Pharmacol 1992; 31(3):205-12.
26. Kodama R, Yano T, Furukawa K, Noda K, Ide H. Studies on the metabolism of d-limonene (p-mentha-1,8-diene). IV. Isolation and characterization of new metabolites and species differences in metabolism. Xenobiotica 1976; 6(6):377-89.
27. Vigushin DM, Poon GK, Boddy A, English J, Halbert W, Pagonis, et al. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Chemother Pharmacol 1998; 42:111-7. (Pubitemid 28267291)
28. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, et al. Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 1998; 4:1159-64. (Pubitemid 28213326)
29. Crowell PL. Monoterpenes in breast cancer chemoprevention. Breast Cancer Res Treat 1997; 46:191-7. (Pubitemid 28029522)
30. Ren Z, Elson CE, Gould MN. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 1997; 54(1):113-20. (Pubitemid 27353228)
31. Jirtle RL, Haag JD, Ariazi EA, Gould MN. Increased mannose 6-phophate/insulin-like grouth factor II receptor and transforming growth factor B1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 1993; 53:3849-52. (Pubitemid 23267674)
32. Wang T, Danielson PD, Li B-y, Shah PC, Kim SD, Donahoe PK. The p21RAS farnesyltransferase a subunit in TGF-b and activin signaling. Science 1996; 271:1120-2.
33. Stayrook KR, McKinzie JH, Burke YD, Burke YA, Crowell PA. Induction of apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis 1997; 18:1655-8. (Pubitemid 28134793)
34. Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, et al. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 1999; 57:801-9. (Pubitemid 29094551)
35. Ripple GH, Gould MN, Arzoomanian RZ, Albert D, Feierabend C, Simon K, et al. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 2000; 6(2):390-6. (Pubitemid 30111455)
36. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 2000; 6(8):3071-80. (Pubitemid 30637730)
37. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18(4):927-41. (Pubitemid 30106625)
38. Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001; 19(4):1167-75. (Pubitemid 32176295)
39. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bok K. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97(11):3361-9.
40. Eummer JT, Gibbs BS, Zahn TJ, Sebolt-Leopold JS, Gibbs RA. Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors. Bioorg Med Chem 1999; 7(2):241-50.
41. Low-Baselli A, Huber WW, Kafer M, Bukowska K, Schulte-Hermann R, Grasl-Kraupp B. Failure to demonstrate chemoprevention by the monoterpene perillyl alcohol during early rat hepatocarcinogenesis: a cautionary note. Carcinogenesis 2000; 21(10):1869-77.